

( (S (NP-SBJ (NP Oncor Inc.)
             ,
             (NP (NP Gaithersburg)
                 ,
                 (NP Md.))
             ,)
     (VP said
         (SBAR 0
               (S (NP-SBJ it)
                  (VP received
                      (NP (NP approval
			      (S *ICH*-2))
                          (PP from
                              (NP the U.S. Food and Drug Administration))
                          (S-2 (NP-SBJ *)
			       (VP to
				   (VP market
				       (NP (NP a genetic test)
					   (SBAR (WHNP-1 that)
						 (S (NP-SBJ *T*-1)
						    (VP will
							(VP assist
							    (PP-LOC-CLR in
									(NP (NP diagnosis and treatment)
									    (PP of
										(NP (NP leukemia)
										    and
										    (NP lymph cancer))))))))))))))))))
     .))
( (SINV (S-TPC-1 (NP-SBJ The B/T gene rearrangement test)
		 (VP is
		     (ADJP-PRD (ADJP more accurate)
			       (PP than
				   (NP existing tests)))
		     (PP for
			 (S-NOM (NP-SBJ *)
				(VP diagnosing
				    (NP (NP (NP the type)
					    (PP of
						(NP cancer)))
					,
					(SBAR (SBAR whether
						    (S (NP-SBJ it)
						       (VP has
							   (VP spread))))
					      or
					      (SBAR whether
						    (S (NP-SBJ there)
						       (VP is
							   (NP-PRD (NP a recurrence)
								   (VP following
								       (NP treatment)))))))))))))
	,
	(VP said
	    (SBAR 0
		  (S *T*-1)))
	(NP-SBJ Oncor President
		Stephen Turner)
	.))
( (S (NP-SBJ Mr. Turner)
     (VP said
         (SBAR 0
               (S (NP-SBJ the test)
                  (VP (VP (ADVP-PRP initially)
			  will
			  (VP be
			      (VP used
				  (PP-MNR in
					  (NP (NP conjunction)
					      (PP with
						  (NP (NP biopsies)
						      and
						      (NP other tests))))))))
		      , 
		      but
		      (VP (ADVP-TMP eventually)
			  might
			  (VP become
			      (NP-PRD (NP the benchmark)
				      (PP for
					  (NP tumor analysis)))))))))
     .))
( (S (NP-SBJ Mr. Turner)
     (VP said
         (SBAR 0
               (S (NP-SBJ-1 the test)
                  (VP will
                      (VP be
                          (VP shipped
                              (NP *-1)
                              (PP-TMP in
				      (NP 45 days))
                              (PP-DIR to
				      (NP (NP hospitals)
					  and
					  (NP clinical laboratories)))))))))
     .))
( (S (NP-SBJ (NP Dr. Wyndham Wilson)
             ,
             (NP (NP a cancer treatment specialist)
                 (PP at
                     (NP the National Cancer Institute)))
             ,)
     (VP said
         (SBAR 0
               (S (NP-SBJ the test)
                  (VP (VP is
			  (VP (ADVP widely)
			      used
			      (PP-LOC-CLR in
					  (NP research centers))))
		      but
		      (VP is n't
			  (VP having
			      (NP a major impact)
			      (SBAR-PRP because
					(S (NP-SBJ it)
					   (VP is
					       (ADJP-PRD (ADVP only occasionally) 
							 useful
							 (PP in
							     (S-NOM (NP-SBJ *)
								    (VP choosing
									(NP the
									    (ADJP most effective)
									    treatment))))))))))))))
     .))
( (S (S-TPC-2 But
	      (NP-SBJ-1 the test)
	      (VP may
		  (VP prove
		      (S (NP-SBJ *-1)
			 (VP to
			     (VP be
				 (ADJP-PRD more sensitive
					   (PP in
					       (S-NOM (NP-SBJ *)
						      (VP determining
							  (SBAR whether
								(S (NP-SBJ a tumor)
								   (VP has
								       (VP spread or returned
									   (PP following
									       (NP treatment))))))))))))))))
     ,
     (NP-SBJ Dr. Wilson)
     (VP said
	 (SBAR 0
	       (S *T*-2)))
     .))
( (S ``
     (S-TPC-1 (NP-SBJ We)
	      (VP do n't
		  (VP know
		      (ADVP-TMP yet)
		      (SBAR (WHADVP-2 how
				      (ADJP useful))
			    (S (NP-SBJ it)
			       (VP 's
				   (VP going
				       (S (NP-SBJ *)
					  (VP to
					      (VP be
						  (ADVP-PRD *T*-2)))))))))))
     , ''
     (NP-SBJ he)
     (VP said
	 (S *T*-1))
     .))
( (S (S-TPC-1 (NP-SBJ (NP Oncor)
		      ,
		      (NP (NP a six-year-old developer)
			  (PP of
			      (NP genetic medical tests)))
		      ,)
	      (VP projects
		  (SBAR that
			(S (NP-SBJ the cancer test)
			   (VP will
			       (VP help
				   (NP it)
				   (S (NP-SBJ *)
				      (VP to
					  (VP post
					      (NP its first-ever profit)
					      (PP-TMP during
						      (NP (NP the first quarter)
							  (PP of
							      (NP 1990)))))))))))))
     ,
     (NP-SBJ Mr. Turner)
     (VP said
	 (SBAR 0
	       (S *T*-1)))
     .))
( (S (S-TPC-1 (NP-SBJ The company)
	      (VP (VP will
		      (VP charge
			  (NP $ 35 *U*)
			  (PP-CLR for
				  (NP a test))))
		  and
		  (VP projects
		      (NP (NP about (QP $ 2 million) *U*)
			  (PP in
			      (NP revenue))
			  (PP from
			      (NP the test))
			  (PP-TMP during
				  (NP (NP the first 12 months)
				      (PP of
					  (NP marketing))))))))
     ,
     (NP-SBJ he)
     (VP said
	 (SBAR 0
	       (S *T*-1)))
     .))
